News

VitalLife Scientific Wellness Center announces a strategic collaboration with Huawei Consumer Business Group (Thailand)

This collaboration marks an important milestone reflecting Huawei’s vision to elevate wearable technology beyond its traditional role as a daily health-tracking tool into becoming part of a broader digital health infrastructure capable of supporting preventive healthcare in a more effective and accessible way. By integrating advanced sensor technology, health data analytics, and medical expertise from leading healthcare partners, the hyperglycemia risk assessment research initiative represents another step forward in empowering consumers to better understand and recognize potential health risks from an early stage. The initiative also aims to promote a more proactive and practical approach to health management that aligns with modern lifestyles.

The collaboration combines the expertise of both organizations. Huawei, as a developer of wearable technologies and digital health platforms, will support participant registration, device management, risk assessment functions, and related digital health services. VitalLife Scientific Wellness Center, as a specialist in preventive medicine and advanced wellness care with internationally recognized healthcare standards, will contribute its expertise in evaluating the potential of wearable-generated data to support preliminary health risk assessment. VitalLife will also support participant selection processes and the assessment of baseline health information.

The project builds upon Huawei’s extensive healthcare research initiatives conducted in China through the Huawei Research Platform, covering multiple health dimensions including cardiovascular health, respiratory health, liver health, hypertension, and other health-related areas. Huawei has collaborated with more than 170 research organizations and engaged over 17 million users, reinforcing confidence that wearable-generated data can provide value beyond fitness tracking and contribute to the advancement of future healthcare research and knowledge development.

Building on the success of previous studies conducted in China, the hyperglycemia risk assessment initiative represents Huawei’s first international expansion of this type of health research. The project aims to explore the potential of wearable devices in supporting preliminary blood glucose risk assessment, helping improve accessibility to early risk screening while encouraging users to become more aware of their health risks at an earlier stage.

Once users voluntarily enroll in the study and provide consent according to the required procedures, the system will begin collecting health-related data from wearable devices over a specified period for analysis and preliminary risk evaluation. Assessment outcomes may be presented in the form of risk levels, such as low risk, high risk, or no preliminary risk detected, enabling participants to better understand their health status in a timely and appropriate manner.

To support the scientific validity and accuracy of the study, selected participants may be contacted by the hospital and invited to undergo additional blood glucose testing. The clinical data obtained will be used to compare smartwatch-generated data with hospital-based clinical results in order to further refine and improve the accuracy of the risk assessment model, with the long-term goal of achieving over 90% model accuracy in the future.

Both parties also aim to further extend the knowledge generated from the study into academic and industry collaboration, supporting broader understanding of preventive healthcare and contributing to the sustainable growth of Thailand’s health technology ecosystem.

The first wearable device supporting this initiative will be the HUAWEI WATCH FIT 5 Pro, which is scheduled to launch in Thailand soon. The device will serve as the first wearable used in this research initiative, reflecting Huawei’s commitment to developing wearable technologies that go beyond conventional fitness smartwatches to become part of an integrated digital health ecosystem capable of supporting proactive healthcare in everyday life through the integration of sensor technology, health data, and research platforms.

The wearable devices used in this project are intended solely for observational research and study purposes and are not intended to replace medical diagnosis, treatment, or professional medical advice from qualified physicians.

For more information and product updates, please visit Huawei Mobile TH on Facebook or access additional product, community, and service information through the My HUAWEI application available on AppGallery.

Reference